课题基金 / 基金详情

Development of gene therapy model of retrovirus-induced disease

Development of gene therapy model of retrovirus-induced disease
逆转录病毒引起的疾病基因治疗模型的开发
批准号:
07670234
负责人:
KITAGAWA Masanobu
金额:
$1.34万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1996

项目摘要

项目成果

KITAGAWA Masanobu的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Fv-4 is a mouse gene that dominantly confers resistance to infection by ecotropic murine leukemia virus (MuLV). Fv-4 resistant (Fv-4^r) gene product was expressed in hematopoietic cells and a part of glandular organs of Fv-4^r-bearing mice. Immunoelectron microscopically, this antigen was expressed on the cell surface and a part of endoplasmic reticulum. Flowcytometric analysis revealed that the Fv-4^r antigen was expressed in erythroid cells, granulocytic cells, T cells and B cells with almost the same intensity. Immunoprecipitaion followed by Western blotting revealed that Fv-4^r gene product existed in the serum of Fv-4^r-bearing mice. The soluble Fv-4^r antigen had a molecular weight of about 80 kDa. The serum Fv-4^r antigen binds to ecotropic MuLV receptors, shown by specific binding to transfectant mink cells expressing ecotropic MuLV receptor, but not to parental mink cells. C3H thymocytes or spleen cells that had ecotropic MuLV receptor and had been preincubated with soluble Fv-4^r antigen were mixed with Friend leukemia virus (FLV). C3H cells treated with Fv-4^r antigen became refractory to binding by FLV.These results provide evidence that the Fv-4^r antigen is released from cells of Fv-4^r-bearing mice in vivo and binds to cells expressing surface receptors for ecotropic MuLV,thereby protecting them from infection with FLV.Next, the implication of these findings for gene therapy of retrovirus-induced disease was examined. Fv-4^r gene was first transduced to leukemia cell line of C3H mouse origin and the cells successfully expressed Fv-4^r antigen. Then, the bone marrow cells of C3H mice were transduced with Fv-4^r gene and transplanted to lethally irradiated C3H mice. The resulting chimera mice expressed Fv-4^r antigen in hematopoietic cells.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kitagawa M.et al.: "Establishment of a therapeutic model for retroviral infection using the genetic resistance mechanism of the host" Pathology International. 46. 719-725 (1996)
Kitakawa M.等人:“利用宿主的遗传抗性机制建立逆转录病毒感染的治疗模型”病理学国际。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masanobu Kitagawa,et al.: "Cell-free transmission of Fv-4 resistance gene product controlling Friend leukemia virus-induced leukemogenesis." Blood. 86. 1557-1563 (1995)
Masanobu Kitakawa 等人:“Fv-4 抗性基因产物的无细胞传递控制弗兰德白血病病毒诱导的白血病发生。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kitagawa M.et al.: "Distribution of Fv-4 resistant gone product in Friend leukemia virus-resistant Fv-4 ^r mouse strain" Experimental Hematology. 24. 1423-1431 (1996)
Kitakawa M.et al.:“Fv-4 抗性消失产物在 Friend 白血病病毒抗性 Fv-4 ^r 小鼠品系中的分布”实验血液学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
6
    Development of novel therapeutic strategy against highly malignant tumors
    • 批准号:
      15K08394
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2015
    • 负责人:
      KITAGAWA Masanobu
    • 依托单位:
    Development of anti-tumor therapy model using MCM2 function
    • 批准号:
      24590476
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.41万
    • 财政年份:
      2012
    • 负责人:
      KITAGAWA Masanobu
    • 依托单位:
    Development of novel therapeutic strategy against tumor progression using animal model
    • 批准号:
      21590432
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2009
    • 负责人:
      KITAGAWA Masanobu
    • 依托单位:
    Enhancement of radiation-induced apoptosis by retroviral infection : implication for the gene therapy
    • 批准号:
      14570180
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.92万
    • 财政年份:
      2002
    • 负责人:
      KITAGAWA Masanobu
    • 依托单位: